



JC037 d PCT/PTO 17 OCT 2005
PTO/SB/10 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

		Application Number	10/520,477
		Filing Date	January 4, 2005
		First Named Inventor	Patrick McGowan
		Art Unit	
		Examiner Name	
Total Number of Pages in This Submission	180	Attorney Docket Number	014875-000002

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Copies of 5 foreign references and 10 publication documents; Acknowledgement Postcard
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Documents	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	MOORE & VAN ALLEN		
Signature			
Printed Name	WILLIAM A. BARRETT		
Date	October 14, 2005	Reg. No.	42,296

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Signature			
Typed or printed name	Katrina Holland	Date	October 14, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Attorney Docket: 014875-000002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Patrick McGowan, et al.

Group Art Unit:

Serial Number: 10/520,477

Examiner:

Filed: January 4, 2005

For: FUNCTIONALIZED METALLOCENES AS ANTICANCER DRUGS

Mail Stop Amendment
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Customer No.: 24,239

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.56 AND 37 C.F.R. § 1.97**

It is respectfully requested that the documents listed on the attached Forms PTO/SB/08a and PTO/SB/08b be considered by the Patent and Trademark Office in the above-referenced application and made of record therein. Full text copies of the relevant documents are enclosed. This information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last.

Respectfully submitted,

By:

William A. Barrett
Registration No. 42,296
Attorney for Applicants
Moore & Van Allen, PLLC
Phone: 919-286-8000
Facsimile: 919-286-8199


October 14, 2005

Date

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the US Postal Service as first class mail on October 14, 2005, in an envelope addressed to Commissioner of Patents, PO Box 1450, Alexandria, VA 22313-1450

Katrina Holland



OCT 17 2005

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

 Substitute for form 1449A/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/520,477
				Filing Date	January 4, 2005
				First Named Inventor	Patrick McGowan
				Art Unit	
				Examiner Name	
Sheet	1	of	2	Attorney Docket Number	
				014875-000002	

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
Sheet	2	of	2	Application Number	10/520,477
				Filing Date	January 4, 2005
				First Named Inventor	Patrick McGowan
				Art Unit	
				Examiner Name	
				Attorney Docket Number	014875-000002

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	A8	PETER JUTZI et al.; Titanium and Zirconium Bent-Sandwich Complexes with the New [2-(Diisopropylamino)ethyl]cyclopentadienyl Ligand: Catalysts for the Polymerization of Ethylene and the Dehydrocoupling of Phenylsilane; Organometallics; 1996; 15, pp. 4153-4161; American Chemical Society		
	A9	PETER JUTZI et al.; Der(N,N-Dimethylaminoethyl)cyclopentadienyl-Ligand in der Komplexchemie von Titan und Zirkon; Journal of Organometallic Chemistry; 1995; 486, pp. 287-289; Elsevier Science S.A.		
	A10	P KÖPF-MAIER et al.; Organometallic titanium, vanadium, niobium, molybdenum and rhenium complexes-early transition metal antitumour drugs; Metal Compounds in Cancer Therapy; Chapter 6, pp. 109-146; Chapman & Hall, London		
	A11	PETRA KÖPF-MAIER, et al.; Vanadocen-dichlorid-ein weiteres Antitumor-Agens aus der Metallocenreihe; Z. Naturforsch; 1979; 34b, pp. 805-807		
	A12	MARGARET M. HARDING et al.; Antitumour Metallocenes: Structure-Activity Studies and interactions with Biomolecules; Current Medicinal Chemistry; 2000; 7, pp. 1289-1303; Bentham Science Publishers Ltd.		
	A13	CV CHRISTODOULOU et al.; Anti-proliferative activity and mechanism of action of titanocene dichloride; British Journal of Cancer; 1998; 77(12) pp. 2088-2097; Cancer Research Campaign		
	A14	JEFFREY H. TONEY et al.; Hydrolysis Chemistry of the Metallocene Dichlorides $M(\eta^5\text{-C}_5\text{H}_5)_2\text{Cl}_2$, $M = \text{Ti}$, V , Zr . Aqueous Kinetics, Equilibria, and Mechanistic Implications for a New Class of Antitumor Agents; J. Am. Chem. Soc.; 1985; 107, pp. 947-953; American Chemical Society		
	A15	ELIZABETH E. TRIMMER et al.; Cisplatin; Essays in Biochemistry; 1999; Vol. 34, Chapter 12, pp. 191-211; Department of Chemistry and Division of Bioengineering and Environmental Health, Massachusetts Institute of Technology		
	A16	JOHN M. VENDITTI; Preclinical Drug Development: Rationale and Methods; Seminars in Oncology; 1981; Vol. 8, No. 4, pp. 349-361; Drug Evaluation Branch, Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, Bethesda, MD		
	A17	M. SATYA MARTHY et al.; Antitumor and Toxicologic Properties of the Organometallic Anticancer Agent Vanadocene Dichloride; Inorganica Chimica Acta; 1988; 152, pp. 117-124; Elsevier Sequoia		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.